Delphinus Medical Technologies Company

Delphinus Medical Technologies develops, commercializes, and services breast cancer screening solutions to hospitals and imaging clinics. Delphinus is striving for a better breast imaging experience for women.
The standard for breast cancer screening in the United States is mammography, yet average mammography compliance in this country is just over fifty percent. In a study from Stanford University Cancer Institute, one-third of respondents were simply not interested in having mammography, possibly due to confusion over the effectiveness of it particularly for women with dense breasts, the debate regarding age-based imaging, fear of it being painful, and the radiation exposure inherent with the exam. SoftVue™ was invented to address these problems. SoftVue™ is PMA approved by the FDA indicated for dense breast cancer screening as an adjunct to mammography.

Investors

Total Funding: $66,729,049
Headquarters: Novi, Michigan, United States
Funding Status: Late Stage Venture
Employee Number: 11-50
Estimated Revenue: $1M to $10M
Last Funding Type: Series C
Last Funding Date: 2017-04-20
Investors Number: 7
Founded Date: 01-01-2010
Industry: General Health Care
Register and Claim Ownership